Johnson & Johnson Pays Sail Biomedicines US$785M Upfront to Develop In Vivo CAR-T Therapies for Autoimmune Disease
By Sanya Sekhri
Pharma Deals Review: Vol 2026 Issue 8 (Table of Contents)
Published: 8 Aug-2026
DOI: 10.3833/pdr.v2026.i8.3033 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a strategic move to strengthen its leadership in immunology and next-generation cell therapies, Johnson & Johnson (J&J) has entered into a collaboration with Sail Biomedicines to advance innovative in vivo CAR-T therapies for immune-mediated diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS